Beyond Genomics Inc (BG) has formed a strategic technology partnership with Micromass UK Limited, a wholly-owned subsidiary of Waters Corporation to expand Beyond Genomics drug discovery research capabilities. Micromass will supply its leading mass spectrometry (MS) technologies to Beyond Genomics, to be utilized in the Company's integrated Systems Biology drug discovery platform.

The partnership agreement includes an equity investment in Beyond Genomics by Waters Corporation, provisions for the purchase of Micromass products by Beyond Genomics, and the opportunity for Micromass to license certain proprietary Beyond Genomics' intellectual property for further development and commercialization. Further details of the agreement were not disclosed.

BG's current research areas include Alzheimer's disease, atherosclerosis and oncology. Earlier this month, the Company completed an $11 million round of equity financing, bringing to $21 million the total equity financing raised to date.

Last week Beyond Genomics and South San Francisco-based diaDexus Inc had announced an agreement to identify new biomarkers and drug targets useful for the diagnosis and treatment of colon, breast and ovarian cancer.